BIOSGN.ST
Price:
$6.05
Market Cap:
$14.21M
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.
Industry
Biotechnology
IPO Date
2021-06-24
Stock Exchange
STO
Ticker
BIOSGN.ST
According to Biosergen AB’s latest financial reports and current stock price. The company's current PE Ratio is -0.61. This represents a change of -77.60% compared to the average of -2.72 of the last 4 quarters.
The mean historical PE Ratio of Biosergen AB over the last ten years is -24.30. The current -0.61 PE Ratio has changed 151.07% with respect to the historical average. Over the past ten years (40 quarters), BIOSGN.ST's PE Ratio was at its highest in in the March 2024 quarter at -0.77. The PE Ratio was at its lowest in in the March 2022 quarter at -5.99.
Average
-24.30
Median
-4.45
Minimum
-141.09
Maximum
-0.57
Discovering the peaks and valleys of Biosergen AB PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 677.28%
Maximum Annual PE Ratio = -0.57
Minimum Annual Increase = -89.92%
Minimum Annual PE Ratio = -141.09
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -2.27 | -65.68% |
| 2024 | -6.63 | 677.28% |
| 2023 | -0.85 | 49.65% |
| 2022 | -0.57 | -87.20% |
| 2021 | -4.45 | -68.71% |
| 2020 | -14.22 | -89.92% |
The current PE Ratio of Biosergen AB (BIOSGN.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.25
5-year avg
-2.95
10-year avg
-24.30
Biosergen AB’s PE Ratio is less than Nanologica AB (publ) (1.76), greater than Biovica International AB (publ) (-1.16), greater than Active Biotech AB (-229.35), greater than NextCell Pharma AB (-2.54), less than Arcoma AB (31.29), greater than Pila Pharma AB (publ) (-2.91), greater than Scandinavian ChemoTech AB (publ) (-14.45), less than Xbrane Biopharma AB (publ) (0.89), less than Sprint Bioscience AB (4.88), greater than SciBase Holding AB (publ) (-1.67),
| Company | PE Ratio | Market cap |
|---|---|---|
| 1.76 | $43.86M | |
| -1.16 | $77.03M | |
| -229.35 | $139.05M | |
| -2.54 | $121.86M | |
| 31.29 | $118.47M | |
| -2.91 | $60.07M | |
| -14.45 | $87.35M | |
| 0.89 | $130.27M | |
| 4.88 | $405.18M | |
| -1.67 | $357.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biosergen AB using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biosergen AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biosergen AB's PE Ratio?
How is the PE Ratio calculated for Biosergen AB (BIOSGN.ST)?
What is the highest PE Ratio for Biosergen AB (BIOSGN.ST)?
What is the 3-year average PE Ratio for Biosergen AB (BIOSGN.ST)?
What is the 5-year average PE Ratio for Biosergen AB (BIOSGN.ST)?
How does the current PE Ratio for Biosergen AB (BIOSGN.ST) compare to its historical average?